Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Grants To Expand Work On Improving Women's Health And Understanding Gender Differences - Yale School of Medicine
Five Yale School of Medicine investigators have received of new Pilot Project Program grants from Women"s Health Research at Yale. They will study a variety of women"s health areas and gender differences that affect disease and behavior.

New Method For Breast Cancer Biomarker Discovery Developed By VBI Researchers
Three researchers from the Virginia Bioinformatics Institute (VBI) at Virginia Tech have developed and evaluated a new one-step bioanalytical approach that allows them to profile in detail complex cellular extracts of proteins. The method has allowed the scientists to look at how the levels of proteins change in breast cancer cells when they are treated with hormones or cancer drugs like tamoxifen.
News of the day
First Patient Of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
Ethicon Endo-Surgery, Inc. announced the successful treatment of the first patient of its IDE feasibility trial. The case, which was performed at The Ohio State University Center for Minimally Invasive Surgery, marks the first natural orifice translumenal endoscopic surgery (NOTES) procedure involving the company"s investigational devices. NOTES is a surgical method in which external incisions are eliminated, potentially leading to reduced pain, a quicker recovery and a faster return to normal activities for the patient.
Endocrinology

ADVTX Announces New Treatment For Bleeding After Nuclear Exposure

Advanced Therapeutics & Co. (ADVTX) announced that Fibrinoplate-S™ has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation. Survivors of a nuclear event or a dirty bomb explosion will have similar damage from the ionizing radiation of such bombs. "Acute radiation can severely damage the bone marrow," Richard Yen, Ph.D., M.D., CEO of ADVTX explained. "While existing medications can boost the production of red cells and white cells from the recovering bone marrow, there is no effective treatment for low concentrations of platelets except through platelet transfusion. Donor platelets, however, may not be available or adequately screened for pathogens during times of distress." Viable Alternative to Platelet Transfusion ADVTX Fibrinoplate-S, a suspension formulation of human albumin spheres coated with a coagulation factor (fibrinogen), mimics the action of activated platelets. Random clots have not been observed even as bleeding improves after the administration of Fibrinoplate-S. In preclinical trials, Fibrinoplate-S reduced bleeding within 2 hours after a bolus intravenous administration in test subjects with less than 1% of the normal platelet count. The beneficial effects last at least 24 hours. There is no need to match the recipients" blood types. Fibrinoplate-S can be given to a large number of patients quickly. Availability ADVTX can scale up its production of Fibrinoplate-S quickly. Government agencies may include Fibrinoplate-S in their emergency response plans by submitting a "pre-EUA" (pre-Emergency Use Approval) to the US FDA. Licensing outside the United States is available. Visit http://www.ADVTX.com. Advanced Therapeutics & Co.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009